Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy
Open accessThe DOI matches its Crossref record; 133 of the 135 references it cites were found in a registry or an index; 50 of the 139 sources its claims cite were checked for support.
Abstract
Gene therapy (GT) for ocular disorders has advanced the most among adeno-associated virus (AAV)-mediated therapies, with one product already approved in the market. The bank of retinal gene mutations carefully compiled over 30 years, the small retinal surface that does not require high clinical vector stocks, and the relatively immune-privileged environment of the eye explain such success. However, adverse effects due to AAV-delivery, though rare in the retina have led to the interruption of clinical trials. Risk mitigation, as the key to safe and efficient GT, has become the focus of ‘bedside-back-to-bench’ studies. Herein, we overview the inflammatory adverse events described in retinal GT trials and analyze which components of the retinal immunological environment might be the most involved in these immune responses, with a focus on the innate immune system composed of microglial surveillance. We consider the factors that can influence inflammation in the retina after GT such as viral sensors in the retinal tissue and CpG content in promoters or transgene sequences. Finally, we consider options to reduce the immunological risk, including dose, modified capsids or exclusion criteria for clinical trials. A better understanding and mitigation of immune risk factors inducing host immunity in AAV-mediated retinal GT is the key to achieving safe and efficient GT.
Overview
CoChat Summary
TL;DR
This review argues that immune responses—especially innate microglial and TLR9-mediated sensing of rAAV DNA/CpG sequences—are key risks for retinal gene therapy and can limit its safety and efficacy. It surveys trial adverse events and mitigation strategies including modified capsids, CpG-depleted/deimmunized vectors, lower doses, immunosuppression, and stricter patient exclusion criteria.
Key findings
- Retinal gene therapy has advanced with one approved product and about 30 active ocular clinical trials; innate and adaptive immune activation is frequent at doses above 1 × 10^11 vg, though humoral antibody responses to transgene products remain rare.
- Dose-dependent toxicity is reported: in the DME trial NCT04418427, high-dose intravitreal ADVM-022 caused increased ocular pressure in 5/12 and vision loss in 1/12; in X-linked retinoschisis, all patients injected with 1 × 10^11 vg displayed anterior chamber inflammation around 2 weeks and vitritis after a month, while only one patient at 1 × 10^10 vg and none at 1 × 10^9 vg developed similar adverse events.
- TLR9/MyD88 is described as the only DNA sensor experimentally proven to trigger rAAV-associated immunity; CpG content varies widely across vector elements (e.g., RF1 11.03% for ITR2, 11.62% for CBA, 10.73% for CAG, 13.83% for HSP, 5.94% for SpCas9, 5.32% for SaCas9). CpG-depleted/deimmunized vectors reduced innate and T cell responses, but in one intraocular study inflammation after 4 × 10^11 vg per eye was only delayed.
- Mitigation options include modified capsids, evading DNA sensing, decreasing dose, immunosuppression (glucocorticoids, rituximab, proteasome inhibitors, hydroxychloroquine), and stricter exclusion criteria such as NAbs above 1:1000, active ocular inflammation, or a history of severe vascular disease.
Methods
- Narrative review, not primary research; it synthesizes published retinal rAAV gene therapy trial immune responses and mechanistic literature on ocular immune privilege, microglia, DNA sensors, and vector/patient risk factors.
- Data include a non-exhaustive Table 1 of retinal GT trials with rAAV vectors and immune responses, and Table 2 calculating RF1 associated with CpG sequences in rAAV vector components (ITRs, promoters, transgenes, supplementary elements).
- Main analysis is qualitative: it compares trial routes and doses, discusses TLR9/MyD88 and other DNA sensors, and proposes risk-mitigation strategies; no systematic search or meta-analysis is described.
Limitations
- Stated: Table 1 is non-exhaustive; little information is available on effector T cell involvement in retinal degenerations; it remains open whether viral particles reach the nucleus in immune cells; there is no consensus on optimal immunomodulatory molecules and dosing; retrospective safety data are not always available; and more uniform adverse-event reporting is needed.
- Evident: as a narrative review, it does not provide new experimental data or quantify effect sizes; the CpG RF1 table is described as not showing direct TLR9 activation risk, which likely depends on CpG-DNA secondary structure.
- Evident: many cited trial results come from press releases or clinicaltrials.gov and may lack peer-reviewed detail; the review does not perform a systematic risk-of-bias assessment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Retinal immune system. (A) In normal immunological conditions, multiple mechanisms are dedicated to immune tolerance and immune privilege. (1) The blood-retina barrier, which is partly composed by tight junctions (depicted in yellow) between RPE cells, acts as a physical and immune bulwark. It blocks the entry of circulating immune cells inside the retina and prevents antigens from escaping the retina [14,15,16]. (2) The retinal microenvironment, composed of immunoinhibitory and trophic factors secreted by the RPE, Müller glial cells, or astrocytes, promotes cell survival and tolerogenic immune responses (impairment of activated T-cell and APC functions, promotion of T-reg induction, and mitigation of inflammatory processes) [8,17,18,19,20,21,22]. (3) Microglial cells, often described as immune wardens, constitute the bulk of the retinal immune cells. They are found in a resting state in the healthy retina [23,24]. (4) Microglial cells are assisted by the complement system, a few resident macrophages and other retinal cells that perform immune surveillance and can act as APCs: Müller glia, astrocytes, or RPE cells [25,26]. While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27,28,29]. (B) During stronger challenges, disruption of the immune privilege may occur. Recruitment and activation of circulating or resident immune cells in the retina, potentially including T cells, usually result in a full-fledged immune response and inflammation, causing permanent tissue damage [30,31].](https://figures.cochat.ai/paper-figures/12a0c634314c456c8b4a832a7ec63175/risk-mitigation-of-immunogenicity-a-key-to-personalized-retinal-gene-therapy-figure-1.jpg)


Verification
Claims the paper makes
40 Valid · 10 Not valid · 57 Not checked · 48 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More recently, innate immune responses elicited by AAV that cause explicit inflammation have started to garner attention, putting into question the impeccable safety record of the recombinant vector [4][5][6].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
What the sources say
- Partly supportedcites [4] Konkle, 2021, BAX 335 Hemophilia B Gene Therapy Clinical Trial Results—Potential Impact of CpG Sequences on Gene Expression, Blood sourceExperimental — accuracy not yet measured
Our copy does support the trend half of the sentence: the Discussion states that 'recent animal studies have unraveled additional innate immune interactions between AAV and host that may be at play and cannot be ignored,' that avoiding immune stimuli in the nucleotide sequence 'is increasingly recognized as an important general consideration,' and that transient IL-6 induction in participant 6 'may be further evidence of an innate immune response triggered by recombinant AAV in humans.' However, the paper never claims this calls the recombinant AAV safety record into question: it hedges its own causal attribution ('we suggest that innate immune stimulation... could have contributed to the loss of AAV vector–mediated gene expression'; 'future research will need to substantiate this hypothesis'), confines the observation to one trial's CpG-enriched BAX 335 cassette, and explicitly argues the vector production platform ran 'without similar incident' in other clinical studies. The citing sentence converts a hedged, single-trial hypothesis into an unhedged general indictment of vector safety, so that framing is not supported by this source. (LLM, conf=0.72)
- Not checked yetcites [5] Reichel, 2017, AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye, Mol. Ther. source
- Supportedcites [6] Shao, W., Earley, L.F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M.L., Ting, J., and Samulski, R.J. (2018). Double-Stranded RNA Innate Immune Response Activation from Long-Term Adeno-Associated Virus Vector Transduction. JCI Insight, 3. source
Our copy treats AAV-elicited innate immunity as an acknowledged, actively investigated concern: the Introduction (p. 1) states 'the innate immune response is immediately activated following AAV vector infection via TLR pathways,' and the Discussion (p. 11) recapitulates that PRR recognition 'upregulates costimulatory molecules and inflammatory cytokine production,' citing rapid inflammatory-cytokine induction after systemic AAV in mice (refs 30, 31) and TLR9/TLR2 activation in pDCs and nonparenchymal liver cells (refs 18, 19). The paper adds new evidence of late IFNβ/dsRNA-pathway activation in primary human hepatocytes (Results, p. 5; Figure 6) and states its results 'highlight the concern that dsRNA-mediated innate immune response is triggered in human hepatocytes from long-term AAV transduction' (Discussion, p. 12), invoking this response as 'an alternative mechanism for therapeutic failure' (p. 2). This matches the cited sentence's substance — inflammatory innate responses to AAV drawing attention and undermining confidence in the recombinant vector; the 'impeccable safety record' phrasing is the citing authors' rhetoric, but the concern it describes is stated in the source. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27][28][29].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 2. Immune Responses in Retinal Gene Therapy Trials
What the sources say
- Not checked yetcites [27] Medzhitov, 2008, Origin and Physiological Roles of Inflammation, Nature source
- Not checked yetcites [28] Xu, 2009, Para-Inflammation in the Aging Retina, Prog. Retin. Eye Res. source
- Supportedcites [29] Chen, 2015, Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration, J. Leukoc. Biol. source
The Introduction states that para-inflammation is an adaptive response of the immune system to low levels of tissue stress, i.e. a low degree of 'danger' stimuli, and the 'Inflammation – an adaptive response to tissue stress' section attributes this term to Medzhitov, describing it as the innate immune response to tissue malfunction (DAMPs sensed by PRRs). The 'Para-inflammatory response by retinal immune system' section applies this to the retina, where resident microglia/macrophages/dendritic cells detect DAMPs and undergo low-level (mild) activation during aging, and the Abstract confirms the retinal innate immune system 'undergoes low levels of activation (para-inflammation)'. The 'Immune privilege property of the retina' section supports the framing that despite tolerance mechanisms, an immune response can still be mounted locally after noxious insults. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An active local or peripheral tolerance to prevent runaway immune responses can be induced in some cases through the conversion of T cell to regulatory T cells (Treg) or the apoptosis of infiltrated effector T cells by inhibitory molecules expressed on the retinal pigmented epithelium (RPE) or resident stromal cells [9][10][11].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
What the sources say
- Not checked yetcites [9] Zamiri, 2005, Thrombospondin Plays a Vital Role in the Immune Privilege of the Eye, Investig. Ophthal. Vis. Sci. source
- Not checked yetcites [10] Griffith, 1996, CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance, Immunity source
- Partly supportedcites [11] Hori, 2006, B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts, J. Immunol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Topical application of CpG ODNs onto a scratched cornea was shown by Chinnery et al. to lead to inflammation in eye tissues including retina, after CpG leakage into the anterior segment [88].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 3.4. The TLR9/MyD88 Pathway Is Activated upon rAAV Transduction
What the sources say
- Supportedcites [88] Chinnery, 2012, TLR9 Ligand CpG-ODN Applied to the Injured Mouse Cornea Elicits Retinal Inflammation, Am. J. Pathol. source
The Results section 'CpG-ODN-Induced Keratitis Is Accompanied by Widespread Intraocular Inflammation' states that CpG-ODN applied to the debrided (scratched) corneal surface caused neutrophil/macrophage infiltration of the anterior uveal tract and anterior chamber plus vitreous haze and inflammatory infiltrates in the vitreous and retina (Figure 3C-I), and the Figure 3 legend dates this to 24 hours after topical application. The section 'CpG-ODN Applied to the Debrided Corneal Surface Quickly Reaches the Retina' and the Discussion support the mechanism in the claim — FITC-labelled CpG-ODN diffused through corneal stroma into the aqueous (anterior segment) and vitreous humour, with fluorescent signal throughout the posterior segment at 24 hours. The only unstated qualifier is the mouse model, which the citing sentence leaves generic. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammatory immune responses for ocular gene therapies become harder to predict in the clinical setting, as both physiological and barrier functions of immune privilege may already be compromised by aging or the ocular disorder physiopathological conditions such as inflammation or oxidative stress induction [21,66,67].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 3.1. Immune Privilege
What the sources say
- Could not verifycites [21] Wang, 2011, Adaptive Müller Cell Responses to Microglial Activation Mediate Neuroprotection and Coordinate Inflammation in the Retina, J. Neuroinflamm. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [66] DiSabato, 2016, Neuroinflammation: The Devil Is in the Details, J. Neurochem. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [67] Verkhratsky, A., Noda, M., and Parpura, V. (2015). Microglia: Structure and Function. Brain Mapping, Elsevier. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
80 more claims · 29 with their cited sources checked
Create a free account to see all 155 claims and to verify the 89 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, subretinal injections have not been associated with severe inflammation following treatment with AAV8, AAV2, or AAV5, increasing its appeal as a route of administration.19,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have observed antidrug antibody responses and inflammation in the eyes due to immune cell infiltration following retinal gene therapy.21,23–27”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immunogenicity against the viral vector that limits gene therapy efficacy is a major concern.4,21,25,26,141 and is one of the biggest exclusion criteria in clinical trials.14,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the clinical setting, screening patients for presence of neutralizing antibodies for the gene therapy vector can improve outcomes.14,26,142”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Although there have been safety issues observed in gene therapy trials outside the eyes, few serious adverse events directly related to recombinant AAV gene therapies have been reported in ocular gene therapy trials.26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [26]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 6. Conclusions and Outlook
“| NCT01496040 | Nantes University Hospital | PI/II, NR, OL | 2 | hRPE65p | hRPE65 | 1.22 × 10 10 to 4.8 × 10 10 | SRI |”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > References
“43. Le Meur, G.; Lebranchu, P.; Billaud, F.; Adjali, O.; Schmitt, S.; Bézieau, S.; Péréon, Y.; Valabregue, R.; Ivan, C.; Darmon, C.; et al. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 5.2.2. Clinical Trial Criteria
“In the recent clinical trial for DME, all patients showing a strong decrease in intraocular pressure at high dose, had a history of severe vascular disease that potentially led to a pro-inflammatory ocular environment [7].”
§ Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy > 1. Introduction
“Five patients suffered from a rapid increase in ocular pressure refractory to conventional drug treatments, leading to surgery for three and to loss of vision for one patient.”
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“…blood Bennett et al. 2012 & 2016 [40,41] NCT00999609 PIII, R, OL 1.5 × 1011 SRI 2/20 with transient mild bilateral inflammation in treated arm N/A Russell et al.2017 [42] NCT00643747 UniversityCollege, London PI/II, NR, OL 2 hRPE65p hRPE65 1 × 10 12 SRI in 5/8 with high dose; anterior…”
InfluentialNeuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
DNA sensing by the cGAS–STING pathway in health and disease
Motwani, M., Pesiridis, S., & Fitzgerald, K. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0151-1 · Cited by 1,467
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Innate immunity to virus infection
Takeuchi, O., & Akira, S. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00737.x · Cited by 1,229
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176
Role of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Helical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling
Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×
“…Therapeutics PI, NR, OL 2 CBA hRPE65v2 1.5 × 1010 to 1.5 × 1011 SRI no inflammation transient increase in nAB in 2/3 patients Maguire et al. 2009 [38] Simonelli et al. 2010 [39] NCT01208389 PI/II, NR, OL (follow-on study: injection of the contralateral eye) 1.5 × 1011…”
InfluentialMicroglial Phagocytosis of Live Neurons
Brown, G. C., & Neher, J. J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3710 · Cited by 853
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 1×
“…University ofOxford PI/II, NR, OL 2 CAG hCHM + WPRE 0.6 × 1010 to 1 × 1011 SRI vector-related inflammation and vitritis in 1/14 at 2wpi; N/A MacLaren et al.2014 [47] NCT02077361 Ian M.MacDonald PI/II, NR, OL 1 × 10 11 SRI 1/6 severe intraretinal inflammation, leading to permanent…”
InfluentialLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 2×
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
BackgroundTemporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution
Mathys, H., Adaikkan, C., Gao, F., Young, J. Z., Manet, E., Hemberg, M., De Jager, P. L., Ransohoff, R. M., Regev, A., & Tsai, L.-H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.039 · Cited by 740 · cited 1×
“Lineage tracing and transcriptomic studies have led to deeper understanding of the microglial activation states (reviewed by Chen et al. 2020; Mathys et al. 2017 [71,72]).”
BackgroundMyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
Para-Inflammation in the Aging Retina
Xu, H., Chen, M., & Forrester, J. V. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.001 · Cited by 659
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639 · cited 2×
“PI/II, NR, OL 5 hRPE65p opt hRPE65opt 1 × 10 11 to 1 × 1012 SRI mild uveitis in 3/9 low, 1/3 intermediate, and 1/3 high dose serious uveitis in 2/3 intermediate dose and 1/3 high dose N/A clinicaltrials.gov 24 November 2021 NCT00481546 University ofPennsylvania PI, NR, OL 2 CBSB hRPE65 5.96 × 1010 to 1.79 × 1011 SRI N…”
BackgroundInfluentialMechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells
Hartmann, G., & Krieg, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.944 · Cited by 605
Microglia-Astrocyte Crosstalk: An Intimate Molecular Conversation
Jha, M. K., Jo, M., Kim, J.-H., & Suk, K. (2019) · The Neuroscientist · doi:10.1177/1073858418783959 · Cited by 579
Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis
Sierra, A., Abiega, O., Shahraz, A., & Neumann, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00006 · Cited by 574
Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553 · cited 1×
“…Therapeutics PI, NR, OL 2 CBA hRPE65v2 1.5 × 1010 to 1.5 × 1011 SRI no inflammation transient increase in nAB in 2/3 patients Maguire et al. 2009 [38] Simonelli et al. 2010 [39] NCT01208389 PI/II, NR, OL (follow-on study: injection of the contralateral eye) 1.5 × 1011 SRI no…”
InfluentialSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
The clinical landscape for AAV gene therapies
Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00017-7 · Cited by 503
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395 · cited 1×
“…eye) 1.5 × 1011 SRI no inflammation transient minor increase in anti-capsid Abs 1/10 no cell-mediated T cell responses detectable in peripheral blood Bennett et al. 2012 & 2016 [40,41] NCT00999609 PIII, R, OL 1.5 × 1011 SRI 2/20 with transient mild bilateral inflammation in treated arm N/A…”
BackgroundInfluentialCD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance
Griffith, T. S., Yu, X., Herndon, J. M., Green, D. R., & Ferguson, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80305-2 · Cited by 382
Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration
Chen, M., & Xu, H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0615-239r · Cited by 381
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368 · cited 1×
“In more serious events, vitreous cells may accumulate near the fovea, leading to a drop in visual acuity and warranting a more prolonged course of corticosteroids [36].”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
The AIM 2 inflammasome: Sensor of pathogens and cellular perturbations
Lugrin, J., & Martinon, F. (2018) · Immunological Reviews · doi:10.1111/imr.12618 · Cited by 333
CNS Infection and Immune Privilege
Forrester, J. V., McMenamin, P. G., & Dando, S. J. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0070-8 · Cited by 313 · cited 1×
“The first line of protection comes from endothelial, epithelial, and glial barriers (reviewed by Forrester et al. 2018 [58]).”
BackgroundIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Immune Regulation in the Aging Retina
Chen, M., Luo, C., Zhao, J., Devarajan, G., & Xu, H. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.10.003 · Cited by 305
CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10
Ruan, G.-X., Barry, E., Yu, D., Lukason, M., Cheng, S. H., & Scaria, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.006 · Cited by 270
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa
Yoshida, N., Ikeda, Y., Notomi, S., Ishikawa, K., Murakami, Y., Hisatomi, T., Enaida, H., & Ishibashi, T. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.006 · Cited by 262
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229 · cited 1×
“…× 1010 IVT 2/3 intraocular inflammation resolved with topical steroid 62% of patients injected with 6 × 109 or 2 × 1010 had increase in anti-AAV2 antibodies Heier et al. 2017 [54] NCT03748784 Adverum Biotechnologies, Inc. PI, NR, OL 2.7m8 CMV aflibercept 2 × 10 11 to 6 × 1011 IVT Ocular…”
Wang, M., Ma, W., Zhao, L., Fariss, R. N., & Wong, W. T. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-173 · Cited by 228
Weleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218 · cited 1×
“…Corp PI/II, NR, OL 2 CBSB hRPE65 1.8 × 1011 to 6 × 1011 SRI in 3 patients, eye inflammation at highest dose Titers of neutralizing antibodies to AAV increased in 5 of 12 patients Weleber et al. 2016 [45] NCT00821340 Hadassah MedicalOrganization PI 2 N/A hRPE65 N/A SRI N/A N/A Int.”
BackgroundInfluentialEngineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 2×
“utilizing TLR9 inhibitory oligonucleotides to avoid immune activation [13].”
MethodA Map of Transcriptional Heterogeneity and Regulatory Variation in Human Microglia
Young, A. M. H., Kumasaka, N., Calvert, F., Hammond, T. R., Knights, A., Panousis, N., Park, J. S., Schwartzentruber, J., Liu, J., Kundu, K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00875-2 · Cited by 213
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208
Gene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Lyons, A., Lynch, A. M., Downer, E. J., Hanley, R., O’Sullivan, J. B., Smith, A., & Lynch, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06253.x · Cited by 202
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
(2008) · PubMed Central · Cited by 183
Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience
Dimopoulos, I. S., Hoang, S. C., Radziwon, A., Binczyk, N. M., Seabra, M. C., MacLaren, R. E., Somani, R., Tennant, M. T. S., & MacDonald, I. M. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.06.011 · Cited by 175
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Microglia versus Monocytes: Distinct Roles in Degenerative Diseases of the Retina
Yu, C., Roubeix, C., Sennlaub, F., & Saban, D. R. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.03.012 · Cited by 168
Hypomethylation of the IL17RC Promoter Associates with Age-Related Macular Degeneration
Wei, L., Liu, B., Tuo, J., Shen, D., Chen, P., Li, Z., Liu, X., Ni, J., Dagur, P., Sen, H. N., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.013 · Cited by 167
Liu, B., Wei, L., Meyerle, C., Tuo, J., Sen, H. N., Li, Z., Chakrabarty, S., Agron, E., Chan, C.-C., Klein, M. L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-111 · Cited by 164
Choroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Good News–Bad News: The Yin and Yang of Immune Privilege in the Eye
Forrester, J. V., & Xu, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00338 · Cited by 153
Constable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152 · cited 1×
“…inflammation and 1 eye inflammation; two ocular aEs were considered possibly related to rAAV. sFLT-1 was eye inflammation, and anterior chamber inflammation, which was mild in nature and resolved without sequelae IFNγ T-cells against capsid in 1/21; 3 seroconverted; Constable et al. 2016 [52] Int.”
BackgroundEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Self-citationAAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Reichel, F. F., Dauletbekov, D. L., Klein, R., Peters, T., Ochakovski, G. A., Seitz, I. P., Wilhelm, B., Ueffing, M., Biel, M., Wissinger, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.018 · Cited by 145 · cited 1×
“This is true for the subretinal injection (SRI) as well as intravitreal (IVT) route of injection, with the latter considered a more immunogenic route [5,35].”
BackgroundThrombospondin Plays a Vital Role in the Immune Privilege of the Eye
Zamiri, P., Masli, S., Kitaichi, N., Taylor, A. W., & Streilein, J. W. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0362 · Cited by 143
Thrombospondin Plays a Vital Role in the Immune Privilege of the Eye
Zamiri, P., Masli, S., Kitaichi, N., Taylor, A. W., & Streilein, J. W. (2007) · Ocular Immunology and Inflammation · doi:10.1080/09273940701382432 · Cited by 137
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137 · cited 1×
“…at D+4 in three patients more significant transient inflammation was observed in two patients anti-AAV4 IgG antibodies in three patients (1 before + 2 after injection) weak and transient cellular response to RPE65 between Le Meur et al. 2018 [43] NCT02781480 MeiraGTx UK IILtd.”
BackgroundSelf-citationNovel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
Innate Immune Response in Retinal Homeostasis and Inflammatory Disorders
Murakami, Y., Ishikawa, K., Nakao, S., & Sonoda, K.-H. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100778 · Cited by 125 · cited 1×
“response and inflammation, causing permanent tissue damage [30,31].”
BackgroundSeeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses
Huang, X., & Yang, Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.501333 · Cited by 121
Shao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
McMenamin, P. G., Saban, D. R., & Dando, S. J. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.12.002 · Cited by 115
Müller Glia Are a Major Cellular Source of Survival Signals for Retinal Neurons in Diabetes
Fu, S., Dong, S., Zhu, M., Sherry, D. M., Wang, C., You, Z., Haigh, J. J., & Le, Y.-Z. (2015) · Diabetes · doi:10.2337/db15-0180 · Cited by 110
Immune regulation in the retina
Detrick, B., & Hooks, J. J. (2010) · Immunologic Research · doi:10.1007/s12026-009-8146-1 · Cited by 109
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108 · cited 2×
“This is true for the subretinal injection (SRI) as well as intravitreal (IVT) route of injection, with the latter considered a more immunogenic route [5,35].”
BackgroundNegative regulators that mediate ocular immune privilege
Taylor, A. W., & Ng, T. F. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0817-337r · Cited by 106
Bouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104
Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity
Zahid, A., Ismail, H., Li, B., & Jin, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613039 · Cited by 100
Müller Glia in Retinal Innate Immunity: A Perspective on Their Roles in Endophthalmitis
Kumar, A., Pandey, R. K., Miller, L. J., Singh, P. K., & Kanwar, M. (2013) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2013006618 · Cited by 99
Immune regulation and the eye.
Stein-Streilein, J. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.08.002 · Cited by 99 · cited 1×
“Among these mechanisms, we can cite a restricted transport of antigens and cells across the blood retinal barrier (BRB), a low level of major histocompatibility complex (MHC) on retinal cells, thus limiting antigen presentation, and the expression of a variety of immunosuppressive factors on ocular antigen-presenting…”
BackgroundBeltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3278 · Cited by 92 · cited 1×
“…serum anti-AAV-2 neutralizing antibody after treatment 1/6 Lam et al. 2019 [49] NCT02671539 STZ eye trial PII, R, OL 2 CAG hCHM + WPRE 1 × 1011 SRI N/A N/A Fischer et al.2019 [50] NCT02407678 University ofOxford PII, R, OL 1 × 10 11 SRI N/A N/A NCT03507686 NightstaRx Ltd. PII, NR, OL N/A…”
Chemical modification of the adeno-associated virus capsid to improve gene delivery
Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., et al. (2020) · Chemical Science · doi:10.1039/c9sc04189c · Cited by 92
Self-citationRonning, K. E., Karlen, S. J., Miller, E. B., & Burns, M. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-41141-0 · Cited by 88
Beguier, F., Housset, M., Roubeix, C., Augustin, S., Zagar, Y., Nous, C., Mathis, T., Eandi, C., Benchaboune, M., Drame-Maigné, A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.021 · Cited by 87
Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
Rogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85
Rossi, A., Dupaty, L., Aillot, L., Zhang, L., Gallien, C., Hallek, M., Odenthal, M., Adriouch, S., Salvetti, A., & Büning, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40071-1 · Cited by 85
Role of Inflammation in Diabetic Macular Edema
Noma, H., Mimura, T., Yasuda, K., & Shimura, M. (2014) · Ophthalmologica · doi:10.1159/000364955 · Cited by 85 · cited 2×
“Inflammation can be induced in some circumstances such as surgical trauma, patient history, disease physiopathology, or upon an escape of intracellular innate immune mechanisms to the immunosuppressive response of the eye [7] (Figure 1).”
BackgroundAAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
Clinical Spectrum of HLA-B27-Associated Ocular Inflammation
Pathanapitoon, K., Dodds, E. M., Cunningham, E. T., & Rothova, A. (2017) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2016.1185527 · Cited by 75
Taylor, A. W., Hsu, S., & Ng, T. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724601 · Cited by 75
IFI16: At the Interphase between Innate DNA Sensing and Genome Regulation
Jakobsen, M. R., & Paludan, S. R. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.06.004 · Cited by 72
Latz, E., Visintin, A., Espevik, T., & Golenbock, D. T. (2004) · Journal of Endotoxin Research · doi:10.1177/09680519040100060501 · Cited by 72
Wu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66
Quantification of CpG motifs in rAAV genomes: Avoiding the toll
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.006 · Cited by 65
Review of Ocular Immune Privilege in the Year 2010: Modifying the Immune Privilege of the Eye
Hori, J., Vega, J. L., & Masli, S. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.512696 · Cited by 64
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Minimal Sequence Requirements for Oligodeoxyribonucleotides Activating Human TLR9
Pohar, J., Kužnik Krajnik, A., Jerala, R., & Benčina, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402755 · Cited by 55
Li, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed · Cited by 52
Inflammation as an Intermediate Pathway in the Association between Psychosocial Stress and Obesity
Hamer, M., & Stamatakis, E. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.03.010 · Cited by 52
Innate Immune Response Gene Expression Profiles of N9 Microglia Are Pathogen-Type Specific
McKimmie, C. S., Roy, D., Forster, T., & Fazakerley, J. K. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.03.012 · Cited by 51
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
TLR9 Ligand CpG-ODN Applied to the Injured Mouse Cornea Elicits Retinal Inflammation
Chinnery, H. R., McLenachan, S., Binz, N., Sun, Y., Forrester, J. V., Degli-Esposti, M. A., Pearlman, E., & McMenamin, P. G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.09.041 · Cited by 46
Sequence-Specific Sensing of Nucleic Acids
Vabret, N., Bhardwaj, N., & Greenbaum, B. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2016.10.006 · Cited by 45
Rituximab for Non-Infectious Uveitis and Scleritis
Ng, C. C., Sy, A., & Cunningham, E. T. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-021-00252-4 · Cited by 40
CRISPR/Cas9-Mediated Phage Resistance Is Not Impeded by the DNA Modifications of Phage T4
Yaung, S. J., Esvelt, K. M., & Church, G. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098811 · Cited by 39
Dufour, V. L., Cideciyan, A. V., Ye, G.-J., Song, C., Timmers, A., Habecker, P. L., Pan, W., Weinstein, N. M., Swider, M., Durham, A. C., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.297 · Cited by 39
Innate immune responses to DNA viruses
Nie, Y., & Wang, Y. (2013) · Protein & Cell · doi:10.1007/s13238-012-2122-6 · Cited by 39
In Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH
Wang, S. K., Lapan, S. W., Hong, C. M., Krause, T. B., & Cepko, C. L. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.003 · Cited by 36
Retinal Pigment Epithelium in Health and Disease
(2020) · doi:10.1007/978-3-030-28384-1 · Cited by 35
Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3 -Mutant Dogs
Ye, G.-J., Komáromy, A. M., Zeiss, C., Calcedo, R., Harman, C. D., Koehl, K. L., Stewart, G. A., Iwabe, S., Chiodo, V. A., Hauswirth, W. W., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.125 · Cited by 28
Song, C., Dufour, V. L., Cideciyan, A. V., Ye, G.-J., Swider, M., Newmark, J. A., Timmers, A. M., Robinson, P. M., Knop, D. R., Chulay, J. D., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.337 · Cited by 28
Library Selection and Directed Evolution Approaches to Engineering Targeted Viral Vectors
Jang, J., Lim, K., & Schaffer, D. V. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21541 · Cited by 26
Morgan, J. I. W., Jiang, Y. Y., Vergilio, G. K., Serrano, L. W., Pearson, D. J., Bennett, J., Maguire, A. M., & Alemán, T. S. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.0158 · Cited by 25
Tobias, P., Philipp, S. I., Stylianos, M., Martin, B., Barbara, W., Felix, R., Alexander, O. G., Eberhart, Z., Marius, U., Birgit, K., et al. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.188 · Cited by 23
Vendomèle, J., Dehmani, S., Khebizi, Q., Galy, A., & Fisson, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00504 · Cited by 18
Qian, Y.-W., Li, C., Jiang, A.-P., Ge, S., Gu, P., Fan, X., Li, T.-S., Jin, X., Wang, J.-H., & Wang, Z.-L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744615 · Cited by 14
The Evolution of Retinal Gene Therapy: From Clinical Trials to Clinical Practice
Pennesi, M. E., & Schlecther, C. L. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.003 · Cited by 12
Microglia: Structure and Function
Verkhratsky, A., Noda, M., & Parpura, V. (2015) · Brain Mapping · doi:10.1016/b978-0-12-397025-1.00356-0 · Cited by 5
Morgan, J. I. W., Jiang, Y. Y., Vergilio, G. K., Serrano, L. W., Pearson, D. J., Bennett, J., Maguire, A. M., & Alemán, T. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.17.459817 · Cited by 1 · cited 3×
“NCT Number Sponsor Study Type (1) Vector Immune Response References Serotype Promoter Transgene Dose (vg) Injection (2) Inflammation Other Choroideremia NCT02341807 SparkTherapeutics PI/II, NR, OL 2 CAG hCHM 5 × 1010 to 1 × 1011 SRI N/A N/A Morgan et al. 2021 [46] NCT01461213 University ofOxford PI/II, NR, OL 2 CAG hC…”
Influential
Research works printed but not linked: 2
- (2021, October 30). Solid Biosciences Announces Clinical Hold on SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy. Available online: https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenne-muscular-dystrophy.
- Michaelides, M., Besirli, C., Khan, K., Yang, Y., Wong, C., Sahel, J., Shah, M., Tee, J., Kumaran, N., and Georgiadis, A. (2020, January 13–15). AAV5-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 12-Month Results From a Phase 1/2 Clinical Trial. Proceedings of the AAO Virtual Meeting, Virtual.
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
“A better understanding and mitigation of immune risk factors that induce host immunity is the key to achieving better clinical results [114].”
BackgroundChauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 27
“Therefore, many investigators are working to develop engineered capsids that evade pre-existing neutralizing antibodies or induce milder immune responses, in the hope that this will allow for more sustained transgene expression and therapeutic benefit at lower doses [48–50].”
BackgroundMannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 18
“35 This dose dependence supports the need of new-generation rAAV vectors with an improved balance between ef fi cacy and safety.”
BackgroundSelf-citationMacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
“53,54 As expected in a safety study of this duration, BCVA was generally maintained in both eyes over 12 months after a single subretinal treatment in each eye.”
Metadata
- Authors
- Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T.
- Affiliations
- Inserm (FR)
- CHU de Nantes, INSERM UMR1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, F-44200 Nantes, France
- Corresponding author
- Adjali, Oumeya
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-26
- Volume
- 22
- Issue
- 23
- Pages
- 12818
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8658027
- OpenAlex
- W3215345544
- Semantic Scholar
- 96613e1fded62606e1613db34a1e7708c2db3238
- Cited by
- 19
- References
- 135
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 6 · 2023: 1 · 2022: 1
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- UpGrade Horizon2020 (825825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- retinal gene therapy, adeno-associated virus vectors, immunogenicity, ocular inflammation, microglia, innate immunity, CpG motifs, dose optimization, exclusion criteria, personalized gene therapy
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Retinal Diseases, Transduction, Genetic, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.